Rachel Lambert-Forsyth appointed as new CEO of British Pharmacological Society
The British Pharmacological Society is delighted to announce the appointment of Rachel Lambert-Forsyth as its new Chief Executive Officer with effect from 16 March 2020.
Rachel is currently Director of Membership and Professional Affairs at the Royal Society of Biology (RSB) and Company Secretary for Charles Darwin House Ltd. Previously, she was Director of Education and Training at the RSB. In 2017, Rachel was appointed to the Department of Education to advise on the content, skills and knowledge required for the healthcare science pathway in its new technical study programmes.
Professor Steve Hill, President of the British Pharmacological Society, said:
I am delighted to be welcoming Rachel to the Society. I think she will be a superb ambassador for our members and for pharmacology, and an open and supportive leader of our staff team. Throughout the extensive appointment process, her commitment to our major strategic objective of embedding equality, diversity and inclusion into all that we do was very clear. She is also firmly signed up to deliver another key aim of our five-year strategy - having fun!
Professor Sir Munir Pirmohamed, President-Elect of the British Pharmacological Society, said:
Rachel’s depth of experience and strong knowledge will no doubt be of great benefit to the Society. She also has an excellent external network, cultivated through her current role, her volunteer non-executive roles and her secondment to government. I am very much looking forward to working with her as I take up my role as President on 1 January 2020.
I’m delighted to be joining the British Pharmacological Society as Chief Executive and to have the opportunity to work with the staff team, Trustees, committees and wider membership to take forward the excellent work led by Jonathan Brüün. It is a privilege to be joining such a dynamic and well-respected organisation. I look forward to building on the current strategic plan, exploring new opportunities which will build a world in which pharmacology and therapeutics drive and support progress in science, medicine and healthcare.
Having built my career at the Royal Society of Biology, I am pleased that I will remain within the biological sciences family and look forward to working across the bioscience disciplines, for the benefit of our members.
Rachel takes the place of current CEO Jonathan Brüün, who leaves the Society on 1 January 2019 to become Chief Executive of the Royal College of Anaesthetists. Mike Poole, who is Finance and Commercial Director at the British Pharmacological Society, has been appointed as Interim CEO until Rachel joins on 16 March 2020.